Identification of genetic variants

1. A method for administering a VEGF-based therapy to a subject, the method comprising administering a VEGF-based therapy selected from bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, pazopanib, and thiazolidinedione to a subject known to have an allelic variant selected from the group consisting of:

i. rs6921438, wherein a guanine residue is present at base 323 of SEQ ID No.1 at one or both alleles,

ii. rs4416670, wherein a thymine residue is present at base 221 of SEQ ID Not at one or both alleles,

iii. rs6993770, wherein a thymine residue is absent at base 235 of SEQ ID No.3 at one or both alleles, and

iv. rs10738760, wherein a guanine residue is present at 201 of SEQ ID No.4 at one or both alleles.

2. A method for administering a VEGF-based therapy to a subject, the method comprising: screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of the allelic variant rs6921438, wherein a guanine residue is detected at base 323 of SEQ ID No.1 at one or both alleles; and administering a VEGF-based therapy to the subject, wherein the VEGF-based therapy is selected from bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, pazopanib, and thiazolidinedione.

3. A method for administering a VEGF-based therapy to a subject, the method comprising: screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of the allelic variant rs4416670, wherein a thymine residue is detected at base 221 of SEQ ID No.2 at one or both alleles; and administering a VEGF-based therapy to the subject, wherein the VEGF-based therapy is selected from bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, pazopanib, and thiazolidinedione.

4. A method for administering a VEGF-based therapy to a subject, the method comprising: screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of the allelic variant rs6993770, wherein a thymine residue is not detected at base 235 of SEQ ID No.3 at one or both alleles; and administering a VEGF-based therapy to the subject, wherein the VEGF-based therapy is selected from bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, pazopanib, and thiazolidinedione.

5. A method for administering a VEGF-based therapy to a subject, the method comprising: screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of the allelic variant rs10738760, wherein a guanine residue is detected at 201 of SEQ ID No.4 at one or both alleles; and administering a VEGF-based therapy to the subject, wherein the VEGF-based therapy is selected from bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, pazopanib, and thiazolidinedione.

6. The method of claim 2 , wherein said screening comprises carrying out an in vitro assay with an array that identifies the presence or absence of the allelic variant.

7. The method of claim 3 , wherein said screening comprises carrying out an in vitro assay with an array that identifies the presence or absence of the allelic variant.

8. The method of claim 4 , wherein said screening comprises carrying out an in vitro assay with an array that identifies the presence or absence of the allelic variant.

9. The method of claim 5 , wherein said screening comprises carrying out an in vitro assay with an array that identifies the presence or absence of the allelic variant.

10. The method of claim 2 , further comprising, prior to said screening, obtaining a biological sample from the subject and isolating nucleic acid from the biological sample, to obtain the nucleic acid sample.

11. The method of claim 3 , further comprising, prior to said screening, obtaining a biological sample from the subject and isolating nucleic acid from the biological sample, to obtain the nucleic acid sample.

12. The method of claim 4 , further comprising, prior to said screening, obtaining a biological sample from the subject and isolating nucleic acid from the biological sample, to obtain the nucleic acid sample.

13. The method of claim 5 , further comprising, prior to said screening, obtaining a biological sample from the subject and isolating nucleic acid from the biological sample, to obtain the nucleic acid sample.

14. The method of claim 10 , wherein said screening comprises polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), isothermic amplification, nucleic acid sequence based amplification (NASBA), 5′ fluorescence nuclease assay, molecular beacon assay, or rolling-circle amplification.

15. The method of claim 11 , wherein said screening comprises polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), isothermic amplification, nucleic acid sequence based amplification (NASBA), 5′ fluorescence nuclease assay, molecular beacon assay, or rolling-circle amplification.

16. The method of claim 12 , wherein said screening comprises polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), isothermic amplification, nucleic acid sequence based amplification (NASBA), 5′ fluorescence nuclease assay, molecular beacon assay, or rolling-circle amplification.

17. The method of claim 13 , wherein said screening comprises polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), isothermic amplification, nucleic acid sequence based amplification (NASBA), 5′ fluorescence nuclease assay, molecular beacon assay, or rolling-circle amplification.

18. The method of claim 14 , wherein the biological sample is a blood sample.

19. The method of claim 15 , wherein the biological sample is a blood sample.

20. The method of claim 16 , wherein the biological sample is a blood sample.

21. The method of claim 17 , wherein the biological sample is a blood sample.